WO2026103337 - NOVEL SUBSTITUTED HETEROCYCLIC COMPOUND AS APELIN RECEPTOR MODULATOR
National phase entry is expected:
Publication Number
WO/2026/103337
Publication Date
21.05.2026
International Application No.
PCT/CN2025/122825
International Filing Date
22.09.2025
Title **
[English]
NOVEL SUBSTITUTED HETEROCYCLIC COMPOUND AS APELIN RECEPTOR MODULATOR
[French]
NOUVEAU COMPOSÉ HÉTÉROCYCLIQUE SUBSTITUÉ EN TANT QUE MODULATEUR DU RÉCEPTEUR DE L'APÉLINE
[Chinese]
作为APELIN受体调节剂的新型取代杂环类化合物
Applicants **
MINDRANK THERAPEUTICS (SUZHOU) NEW DRUG RESEARCH AND DEVELOPMENT CO., LTD
Inventors
ZHANG, Long
Priority Data
202411630773.8
15.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2130 | |
| EPO | Filing, Examination, Granting | 13622 | |
| Japan | Filing, Examination, Granting | 2029 | |
| South Korea | Filing, Examination, Granting | 1870 | |
| USA | Filing, Examination, Granting | 5190 |
Total:
24,841
Contact Us
Abstract[English]
Disclosed in the present invention is a compound having significant Apelin receptor modulation activity, and specifically disclosed is a compound represented by the following formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, isotopologue, or isomer thereof.[French]
La présente invention concerne un composé présentant une activité significative de modulation du récepteur de l'apéline, et concerne plus particulièrement un composé représenté par la formule (I) suivante, ou un sel, solvate, hydrate, isotopologue ou isomère pharmaceutiquement acceptable de celui-ci.[Chinese]
本发明公开了具有显著的Apelin受体调节活性的化合物，具体公开了如下式(I)结构所示化合物或其药学上可接受的盐、溶剂合物、水合物、同位素取代物或其异构体。